Philip A. Thompson, M.B., B.S.

Peer-Reviewed Articles

1. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
2. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
3. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2017. PMID: 29178361.
4. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2017. PMID: 29164608.
5. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer 122(16):2505-11, 2016. e-Pub 2016. PMID: 27182988.
6. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma 57(7):1-9, 2016. e-Pub 2015. PMID: 26472485.
7. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2015. PMID: 26588193.
8. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303-9, 2016. e-Pub 2015. PMID: 26492934.
9. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
10. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
11. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc 90(10):1440-54, 2015. PMID: 26434969.
12. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
13. Thompson PA, May D, Choong PF, Tacey M, Liew D, Cole-Sinclair MF. Predicting blood loss and transfusion requirement in patients undergoing surgery for musculoskeletal tumors. Transfusion 54(6):1469-77, 2014. e-Pub 2014. PMID: 24411009.
14. Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, Szer J, Ritchie D, Bajel A. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20(6):781-6, 2014. e-Pub 2014. PMID: 24548876.
15. Doo NW, Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Joyce T, Harrison SJ. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 54(7):1465-72, 2013. e-Pub 2012. PMID: 23121086.
16. McKelvie PA, Thompson PA, Tam CS. Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre. Histopathology 61(2):212-23, 2012. e-Pub 2012. PMID: 22716228.
17. Howman R, Thakerer A, Pitman M, Ding N, Thompson PA, Khot A, Harrison SJ. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy. Leuk Lymphoma 51(12):2299-302, 2010. e-Pub 2010. PMID: 20929329.

Invited Articles

1. Thompson PA, Tam CS. Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL. Oncology (Williston Park) 32(6):291-2, 294-6, 2018. PMID: 29940059.
2. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic endpoint: working toward cure for patients with CLL. Blood 127(3):279-86, 2016. e-Pub 2015. PMID: 26576865.
3. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 2015. PMID: 26039209.
4. Thompson PA, Shpall EJ, Keating MJ. Shifting paradigms in the treatment of chronic lymphocytic leukemia. Future Oncol 11(4):641-57, 2015. PMID: 25686119.
5. Thompson PA, Prince HM. Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis. Curr Hematol Malig Rep 8(3):196-210, 2013. PMID: 23765424.
6. Best G, Thompson P, Tam CS. Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma 53(11):2105-15, 2012. e-Pub 2012. PMID: 22568511.

Editorials

1. Thompson PA. MRD negativity as a surrogate for PFS in CLL?. Blood 131(9):943-944, 2018. PMID: 29496697.
2. Thompson PA, Tam CS. CD38 expression in CLL: a dynamic marker of prognosis. Leuk Lymphoma 55(1):1-2, 2014. PMID: 23540343.
3. Thompson PA, Tam CS, Thursky K, Seymour JF. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma 51(9):1592-5, 2010. PMID: 20807092.

Abstracts

1. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for CLL: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Presented at the IWCLL Young Investigators Meeting, Sydney, Australia (oral presentation), 2015.
2. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Champlin R, Shpall EJ, Hosing CM. Complex karyotype in chronic lymphocytic leukemia is associated with a high relapse rate post-allogeneic stem cell transplant but durable complete remissions are achieved by immunomanipulation. Presented at the IWCLL, Sydney, Australia (poster presentation), 2015.
3. Thompson PA, Keating MJ, Hinojosa C, Smith S, Jain N, Burger J, Estrov Z, O'Brien SM, Wierda WG, Kantarjian HM, Ferrajoli A. Lenalidomide and rituximab in combination as first-line treatment of CLL: initial results of a phase II study. Presented at the IWCLL, Sydney, Australia (poster presentation), 2015.
4. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi A, Ciurea S, Champlin RE, Ashish Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Results of allogeneic double umbilical cord blood transplantation for relapsed and refractory Hodgkin's lymphoma. Biology of Blood and Marrow Transplant 21(2):S48, 2015.
5. Shaim H, Estrov Z, Sekine T, Kondo K, Ruvolo PP, Thompson P, Sarvaria A, Muftuoglu M, Imahashi N, Liu E, Sobieski C, Wierda W, Keating MJ, Shah N, Hosing CM, Alsuliman A, Basar R, Ferrajoli A, Shpall EJ, Rezvani K. The CXCR4/STAT3/IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia (CLL) and can be modulated by lenalidomide. Blood 126(23):1709, 2015.
6. Kondo K, Burger JA, Keating M, Tran J, Muftuoglu M, Daher M, Shaim H, Thompson P, Imahashi N, Alsuliman A, Wierda W, Liu E, Shpall EJ, Rezvani K. Ibrutinib can modulate the T cell response in chronic lymphocytic leukemia by reducing PD1/PDL1 interactions. Blood 126(23):#1737, 2015.
7. Jain P, Keating MJ, Cleeland C, Renner S, Xuelin H, Gonzalez GN, Harris DM, Wierda W, DiNardo C, Pemmaraju N, Jain N, Thompson P, Ferrajoli A, Burger JA, Kantarjian HM, Verstovsek S, Estrov Z. Ruxolitinib reduces cytokine/chemokine levels and improves fatigue and chronic lymphocytic leukemia (CLL)-related symptoms in CLL patients not requiring systemic therapy. Blood 126(23):2943, 2015.
8. Rozovski U, Harris DM, Li P, Liu Z, Ferrajoli A, Burger JA, Thompson P, Jain N, Wierda W, Keating M, Estrov Z. Stimulation of the B-cell receptor (BCR) induces successive activation of STAT3 and nuclear factor-Kappa-B in CLL cells. Blood 126(23):4125, 2015.
9. Rozovski U, Harris DM, Li P, Liu Z, Ferrajoli A, Burger JA, Thompson P, Jain N, Wierda W, Keating M, Estrov Z. P300 acetylates STAT3 and increases its constitutive transcriptional activity in CLL cells. Blood 126(23):4143, 2015.
10. Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Estrov Z, et al.. Beta-2 microglobulin is a dynamic marker of prognosis during treatment with FCR or ibrutinib-based regimens. Haematologica 99((s1)):57 (Poster presentation), 2014.
11. Thompson PA, Ferrajoli A, O'Brien SM, Wierda WG, Keating M, Burger JA. Trisomy 12 is associated with a distinct pattern of lymphocytosis during treatment with ibrutinib, which does not affect response depth or duration. Haematologica 99((s1)):316-317 (poster presentation), 2014.
12. Thompson PA, Rosovski U, Keating MJ, Wierda WG, Falchi L, O'Brien SM, Ferrajoli A. The addition of CD20 monoclonal antibody to lenalidomide improves response rate, TTF and survival in relapsed and refractory CLL. Haematologica 99((s1)):250-251 (Oral presentation), 2014.
13. Thompson PA, Wierda WG, Ferrajoli A, Smith SC, O'Brien SM, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype, rather than del[17p] is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens. Blood 124:22, 2014.
14. Thompson PA, Keating MJ, Hinojosa C, Smith SC, Daver N, Jain N, Burger JA, Estrov Z, O'Brien SM, Wierda WG, Kantarjian HM, Ferrajoli A. Lenalidomide and rituximab in combination as initial treatment of chronic lymphocytic leukemia: initial results of a phase II study. Blood 124:1988 (Poster presentation), 2014.
15. Badar T, Thompson PA, George B, Daver N, Borthakur G, Cortes JE, Konopleva M, Kadia TM, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Kantarjian HM, Patel KP, Luthra R, Sukholutsky V, Garcia-Manero G. Temporal acquisition of FLT3-ITD or RAS mutation at transformation to AML from MDS: clinical implications. Blood 124:4631 (Poster presentation), 2014.
16. Randhawa JK, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreef M, Levis M, Ravandi F, Cotes JE. Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (pts) with activating FLT3 mutations. Blood 124:1927 (Oral presentation), 2014.
17. Bajel AR, Curley C, Lim ABM, Handunnetti S, Getta B, Thompson PA, Wright MPF, Greenwood M, Hertzberg M, Curtis DJ, Szer J, Kennedy GA, Ritchie D. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia - a multicentre Australian experience: prognostic factors for survival and relapse. Blood 124:1927 (Poster presentation), 2014.
18. Thompson PA, Lim A, Tacey M, Hijazi R, Ng AP, Szer J, et al.. Screening with spirometry is a useful predictor of later development of non-infectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Presented at the Haematology Society of Australia and New Zealand Conference, Gold Coast, Australia:(Oral presentation), 2013.
19. Thompson PA, Lim A, Tacey M, Hijazi R, Ng AP, Szer J, et al.. Screening with spirometry is a useful predictor of later development of non-infectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Blood 122:4603, Abstract 722 (poster presentation), 2013.
20. Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Peinert S, Joyce T, Harrison SJ. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Presented at 2009 HAA annual scientific meeting, 2009.

Book Chapters

1. Thompson PA, Rezvani K, Kebriaei P. Cellular therapy in allogeneic hematopoietic cell transplantation. In: MD Anderson Manual of Medical Oncology. McGraw-Hill, 2015.

Letters to the Editor

1. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 170: 125-8, 2015.
2. Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K, Wolf M, Peinert S, Joyce T, Harrison SJ. Bortezomib added to high dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 46: 764-65, 2011.
3. Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica 95: 1977-9, 2010.
4. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol.